Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
By Rafael Rosell, Laia Perez-Roca, Jose Javier Sanchez, Manuel Cobo, Teresa Moran, Imane Chaib, Mariano Provencio, Manuel Domine, Maria Angeles Sala, Ulpiano Jimenez, Pilar Diz, Isidoro Barneto, Jose Antonio Macias, Ramon de las Peñas, Silvia Catot, Dolores Isla, Jose Miguel Sanchez, Rafael Ibeas, Guillermo Lopez-Vivanco, Juana Oramas, Pedro Mendez, Noemi Reguart, Remei Blanco and Miquel Taron
(2007). Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.
(2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
(2005). Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
(2001). BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.
(2006). BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
(1999). BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.
(2003). BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
(2004). BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
(2007). BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy.
(1998). BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
(2007). BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer.
(2004). Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.
(2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
(2008). Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancerspecific alleles of EGFR and KRAS.
(2007). Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
(2004). EGF receptor gene mutations are common in lung cancers from ‘‘never smokers’’ and are associated with sensitivity of tumors to gefitinib and erlotinib.
(2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
(2005). EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
(2004). Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases.
(2008). ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
(2008). Firstline gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
(2008). HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response.
(2007). Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
(2004). Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
(2001). Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
(2006). Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
(2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
(2007). Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
(2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
(2007). RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.
(2000). The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
(2007). The DNA damage response: ten years after.
(2007). The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response.
(2008). Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
(2007). Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage.